NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

BACKGROUND: Glioblastoma and tumor endothelial cells express phosphatidylserine, a highly immunosuppressive membrane phospholipid. Bavituximab a chimeric monoclonal antibody binds to 2-glycoprotein 1 (2-GP1) to form a complex of 2-GP1 with phosphatidylserine, resulting in immune activation against t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Ly, Ina, Cardona, Jonathan, Beers, Andrew, Chang, Ken, Brown, James, Reardon, David, Arrillaga-Romany, Isabel, Dietrich, Jorg, Forst, Deborah, Lee, Eudocia, Jordan, Justin, Nayak, Lakshmi, Wen, Patrick, Batchelor, Tracy, Kalpathy-Cramer, Jayashree, Gerstner, Elizabeth
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216505/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.792
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg